Matrix Metalloproteinases (MMPs) in patients with pulmonary tuberculosis (PT) and comorbid COPD Source: International Congress 2018 – Tuberculosis comorbidities Year: 2018
Matrix metalloproteinases (MMPs) and acute phase proteins (APP) in predicting the efficacy of intensive phase treatment (IPP) in patients with pulmonary tuberculosis (PT) Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Matrix metalloproteinase- 9 (MMP-9) and tissue inhibitor of metalloproteinase-1(TIMP-1) as non-invasive biomarkers of remodelling in asthma Source: International Congress 2015 – Phenotyping asthma with biomarkers Year: 2015
Expression of adamalysin proteases (A Disintegrin And Metalloprotease) and their inhibitors in sputum from asthmatics Source: Eur Respir J 2006; 28: Suppl. 50, 445s Year: 2006
Matrix metalloproteinase (MMP) 12 is associated with clinical parameters of disease severity and exacerbations in asthma Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010
Matrix metalloproteinases (MMPs) and angiogenesis in lung tissue remodeling in different variants of idiopathic interstitial pneumonia (IIP) Source: Eur Respir J 2007; 30: Suppl. 51, 137s Year: 2007
Plant proteinase inhibitor from crataeva tapia (CrataBl) attenuates inflammation and remodelling induced by elastase in mice Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013
Late Breaking Abstract - Matrix metalloproteinases in serum and sputum reflect distinct processes of relevance to asthma Source: International Congress 2019 – Precision meets immunology in treatment of airway diseases Year: 2019
Metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs) and transforming growth factor (TGFβ) in pleural tuberculosis Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008
Induced sputum (IS) MMP- 9 and TIMP- 1 in granulomatous diseases Source: Eur Respir J 2001; 18: Suppl. 33, 409s Year: 2001
Blood levels of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix matalloproteinases (TIMPs) as biomarkers of COPD. Source: International Congress 2018 – Functional genomics and COPD: new challenges Year: 2018
Relationship between the Matrix Metalloproteinases (MMPs) levels and lung mechanic parameters established by impulse oscillometry (IOS) in patients with pulmonary tuberculosis (TB) Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020
Matrix metalloproteinases gene polymorphisms in the pathogenesis of primary spontaneous pneumothorax Source: Annual Congress 2013 –Genetics and genomics of lung disease Year: 2013
Metalloproteinase-9 and tissue inhibitor of metalloproteinase in baker‘s asthma Source: Eur Respir J 2005; 26: Suppl. 49, 603s Year: 2005
Matrix metalloproteinases in tuberculosis Source: Eur Respir J 2011; 38: 456-464 Year: 2011
Lung overexpression of matrix metalloproteinase-2 protects against bronchial asthma Source: International Congress 2015 – Asthma mechanisms and management Year: 2015
Genes of detoxication system, matrix metalloproteinase 9 (MMP9) and set of group factors of blood in the risk of development of COPD Source: Eur Respir J 2004; 24: Suppl. 48, 63s Year: 2004
Matrix metalloproteinases, as markers of the severity of idiopathic pulmonary fibrosis Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019
A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? Source: Eur Respir J 2011; 38: 1200-1214 Year: 2011